Union européenne - norvégien - EMA (European Medicines Agency)

zentiva, k.s. - pregabalin - anxiety disorders; epilepsy - antiepileptics, - neuropathic pain , pregabalin zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , epilepsy , pregabalin zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , generalised anxiety disorder , pregabalin zentiva is indicated for the treatment of generalised anxiety disorder (gad) in adults.

Norvège - norvégien - Statens legemiddelverk

menarini international o.l. s.a. - nebivololhydroklorid - tablett - 5 mg

Norvège - norvégien - Statens legemiddelverk

menarini international o.l. sa - nebivololhydroklorid / hydroklortiazid - tablett, filmdrasjert - 5 mg / 12.5 mg

Union européenne - norvégien - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastiske midler - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Norvège - norvégien - Statens legemiddelverk

viatris as - verapamilhydroklorid - tablett, filmdrasjert - 40 mg

Norvège - norvégien - Statens legemiddelverk

viatris as - verapamilhydroklorid - tablett, filmdrasjert - 80 mg

Norvège - norvégien - Statens legemiddelverk

mylan healthcare norge as - verapamilhydroklorid - tablett, filmdrasjert - 120 mg

Norvège - norvégien - Statens legemiddelverk

viatris as - verapamilhydroklorid - depottablett - 240 mg

Norvège - norvégien - Statens legemiddelverk

viatris as - verapamilhydroklorid - depottablett - 120 mg

Union européenne - norvégien - EMA (European Medicines Agency)

krka d.d. - pemetrexed disodium - carcinoma, non-small-cell lung; mesothelioma - antineoplastiske midler - ondartet pleural mesotheliomapemetrexed krka i kombinasjon med cisplatin er angitt for behandling av kjemoterapi naive pasienter med inoperabel ondartet pleural mesothelioma. non-small cell lung cancerpemetrexed krka i kombinasjon med cisplatin er angitt for det første-linje behandling av pasienter med lokalt avansert eller metastatisk ikke-liten celle lunge kreft annet enn overveiende plateepitelkreft histology. pemetrexed krka er indisert som monoterapi for vedlikehold behandling av lokalt avansert eller metastatisk ikke-liten celle lunge kreft annet enn overveiende plateepitelkreft histology hos pasienter med sykdommen har ikke kommet umiddelbart etter platinum-basert kjemoterapi. pemetrexed krka er indisert som monoterapi for andre-linje behandling av pasienter med lokalt avansert eller metastatisk ikke-liten celle lunge kreft annet enn overveiende plateepitelkreft histology.